NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel ...

A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent tumor-specific immune responses, supporting flexible cancer vaccine design ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Gold-antibody conjugates for use in malaria diagnostics were prepd. and a method of characterization that can be applied to any gold-protein conjugate was developed. When protein adsorbs onto a gold ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

DB-1310, a HER3-targeted antibody-drug conjugate, demonstrated antitumor activity in heavily pretreated patients with advanced solid tumors, including EGFR-mutant non-small cell lung cancer.

EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumor-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showed promising efficacy data ...

In this video, Sonali M. Smith, MD, discusses several notable studies on new treatment combinations and other options for ...

When conjugated to antibodies, dKIF976 DACs exhibited antigen-dependent KIF11 degradation and cell growth inhibition, with enhanced potency observed in cell lines with high target expression.

Sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) are antibody-drug conjugates (ADCs) approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic breast ...